IMMUNOLOGY AND CANCER

免疫学与癌症

• 批准号: 8486612
• 负责人: MICHELLE M LE BEAU
• 金额: $ 1.83万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-04-01 至 2018-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8486612
• 关键词: Antibodies; Antigen Presentation; Antigen Targeting; Antigens; Back; Biological Markers; Biological Models; Blood; Cancer Center Support Grant; Cancer Immunology Science; Cancer Patient; Cancer Vaccines; Cell physiology; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Core Facility; Cyclic GMP; Development; Direct Costs; Environment; Fostering; Funding; Goals; Heterogeneity; Human; Immune; Immune Tolerance; Immune response; Immune system; Immunologic Monitoring; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Inflammation; Instruction; Intervention; Journals; Knowledge; Laboratories; Lead; Lymphocyte; Lymphocyte Activation; Maintenance; Malignant Neoplasms; Mediating; Memory; Mind; Modeling; Molecular; Monitor; Monoclonal Antibodies; Mus; Natural Immunity; Outcome; Pathway interactions; Patients; Peer Review; Peripheral; Phase; Pre-Clinical Model; Process; Property; Publications; Publishing; Regulation; Regulatory Pathway; Research; Research Personnel; Research Project Grants; Series; Site; Source; T-Lymphocyte; Tissues; Translating; Translational Research; Tumor Antigens; Tumor Immunity; cancer cell; cancer therapy; clinical application; fundamental research; immune activation; immunoregulation; in vivo; killings; melanoma; member; mouse model; novel; novel therapeutic intervention; peripheral tolerance; pre-clinical; programs; trafficking; translational approach; tumor; tumor immunology; tumor microenvironment

The Immunology and Cancer (IC) Program has been an integral part of the UCCCC for more than 25 years. It has 22 members from 6 Departments, and is supported by a total of $13,081,506 in annual peer reviewed funding (direct costs), of which $2,351,962 comes from the NCI. Over the previous funding period (encompassing 4 years). Program members have produced a total of 219 peer-reviewed cancer relevant publications, with 29% published in the highest impact journals; 18% of these were interprogrammatic and 9% were intraprogrammatic. The broad goals of the Immunology and Cancer Program are to understand the interface between the host immune system and a malignant tumor and, ultimately, to manipulate that interaction to promote immune-mediated tumor destruction in patients with cancer. It is well established that tumors can express antigens that can be recognized by specific T cells or antibodies. Identifying the reasons why a given cancer is not eliminated spontaneously should highlight the major barriers that need to be overcome in order to restore immune control over the tumor. The research themes of the program focus on understanding the mechanisms of innate immune activation and productive antigen presentation; activation and differentiation of lymphocytes into effector/memory states; trafficking into inflamed target tissues and control of local inflammation; and overcoming mechanisms of peripheral immune tolerance. Basic concepts are integrated into mouse preclinical tumor models, and novel clinical trials are performed to capitalize on this new knowledge translationally, many in collaboration with clinical investigators outside of the Program. The clinical/translational effort is supported by several key Core Facilities, in particular the Human Immunologic Monitoring-cGMP Facility. By incorporating detailed scientific endpoint monitoring into clinical studies, new key information is generated that has led to the development of new hypothesess that are interrogated back in the laboratory. Thus, the Immunology and Cancer Program is a clear example of bi-directional translational research.

免疫学和癌症（IC）计划已成为UCCCC的一个组成部分超过25年。它有来自6个部门的22名成员，每年的同行评审资金（直接费用）总额为13,081,506美元，其中2,351,962美元来自NCI。在上一个资助期间（包括4年）。项目成员共发表了219篇经同行评审的癌症相关论文，其中29%发表在最具影响力的期刊上；其中18%是方案间的，9%是方案内的。